Replies to post #148813 on Biotech Values

[DewDiligence]

Teva halts Rituxan FoB program:

http://www.haaretz.com/business/teva-halts-tests-of-cancer-drug-biosimilar.premium-1.468148

It’s unclear whether this was a technical decision or a business decision. It could well be the latter insofar as there are multiple companies vying for non-interchangeable Rituxan FoB’s, so the profit margins after sales and marketing costs would seem to be meager.